Apomorphine treatment is a key unmet need for PD sufferers in India. King’s is bringing their expertise and knowledge to address this gap in treatment offered in India.
Parkinson’s disease (PD) is generally seen as a movement disorder caused by degeneration of some brain structures and decreased dopamine. Current therapies focus mainly on the classic motor symptoms (such as shaking, stiffness and slowness of movement) and include mainly dopaminergic drugs like levodopa and dopamine agonists. One of these agonists is Apomorphine and is currently prescribed only for patients at advanced stages of PD where conventional drug therapies are no longer sufficient.
King’s is one of the leading centres in the UK providing this therapy. Prof K Ray Chaudhuri is a leading clinician and facilitator of introducing Apomorphine in India. King’s is sharing their Centre of Excellence expertise and provides clinical and academic training for the teams joining the Apomorphine pathway project.